Korea S.E.
03:30:00 04/07/2024 am IST
5-day change
1st Jan Change
13,250
KRW
+0.91%
+2.71%
+18.09%
Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on July 31, 2019.
From July 31, 2019 to September 30, 2019, the company has repurchased 253,328 shares, representing 3.38% for KRW 4,441 million. With this, the company has completed the repurchase of 253,328 shares, representing 3.38% for KRW 4,441 million under the buyback announced on July 31, 2019.
Cell Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
15/23/15
CI
Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on February 18, 2022.
18/22/18
CI
Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on February 18, 2022.
18/22/18
CI
Cell Biotech Co., Ltd.'s Equity Buyback announced on February 18, 2022, has expired with 227,719 shares, representing 3.24% for KRW 3,718.70 million.
18/22/18
CI
Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on February 18, 2022.
19/22/19
CI
Cell Biotech Co., Ltd. announces an Equity Buyback for KRW 5,000 million worth of its shares.
18/22/18
CI
Cell Biotech Co., Ltd. authorizes a Buyback Plan.
18/22/18
CI
Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on July 31, 2019.
30/21/30
CI
Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on July 31, 2019.
30/21/30
CI
Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on July 31, 2019.
30/21/30
CI
Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on July 31, 2019.
30/21/30
CI
Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on July 31, 2019.
30/21/30
CI
Cell Biotech Co., Ltd.'s Equity Buyback announced on July 31, 2019, has expired with 432,381 shares, representing 5.8% for KRW 7,328 million.
29/21/29
CI
Cell Biotech Acquire a European Patent for Anticancer Protein P8 Originated from Lactobacillus rhamnosus
06/21/06
CI
Cell Biotech Co., Ltd.'s Equity Buyback Plan Extended till July 29, 2021.
29/21/29
CI
Cell Biotech Co., Ltd.(KOSDAQ:A049960) dropped from S&P Global BMI Index
21/20/21
CI
Cell Biotech Co., Ltd.'s Equity Buyback Plan Extended till January 29, 2021.
29/20/29
CI
Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on July 31, 2019.
30/20/30
CI
Psomagen and Cell Biotech to Enter into Agreement
21/20/21
CI
Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on July 31, 2019.
31/20/31
CI
Cell Biotech Co., Ltd.'s Equity Buyback Plan Extended till July 29, 2020.
30/20/30
CI
Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on July 31, 2019.
31/19/31
CI
Tranche Update on Cell Biotech Co., Ltd.'s Equity Buyback Plan announced on July 31, 2019.
30/19/30
CI
Cell Biotech Co., Ltd. announces an Equity Buyback for KRW 10,000 million worth of its shares.
31/19/31
CI
Cell Biotech Co., Ltd. authorizes a Buyback Plan.
31/19/31
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
CELLBIOTECH Co., Ltd is a Korea-based company engaged in the manufacturing of bio products. The Company's products include lactic acid bacteria (LAB) powders and finished products containing LABs. Its LAB powders are used as raw materials in foods and medicines for the functions of immunization enhancement and digestion improvement. Its finished products containing LABs are used for intestinal health improvement, carcinogen inhibition, calcium supplement and others. The Company distributes its products within domestic market and to overseas markets.
More about the company
1st Jan change
Capi.
+18.09% 64.91M +15.58% 121B +16.60% 110B +17.73% 25.93B -24.33% 19.27B -19.35% 16.01B -17.95% 15.66B -48.32% 14.89B +58.78% 14.47B +4.91% 13.91B
Bio Therapeutic Drugs
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
CELL BIOTECH CO., LTD. 
